Valuation: Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Market Cap 3.81B 572M 513M 475M 430M 803M 54.5B 813M 5.67B 2.26B 28.52B 2.15B 2.1B 90.53B P/E 2024
506x
P/E 2025 -55.7x
Enterprise Value 4.82B 723M 648M 599M 543M 1.01B 68.83B 1.03B 7.17B 2.85B 36.02B 2.71B 2.65B 114B EV / Sales 2024
6.63x
EV / Sales 2025 7.43x
Free-Float
37.78%
Yield 2024 *
-
Yield 2025 -
06:18pm Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Announces Changes to Its Board CI
04-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-23 Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
01-14 Bohui Innovation Biotechnology Gets Clinical Trial Approval for Anti-Rabies Human Rabies MT
11-12 Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine MT
29/10/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
27/08/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
02/06/25 Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit MT
28/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
1 day+0.86%
1 week-2.51%
Current month-10.71%
1 month-9.67%
3 months+0.65%
6 months-16.01%
Current year-25.52%
1 week 4.39
Extreme 4.39
4.86
1 month 4.39
Extreme 4.39
5.34
Current year 4.06
Extreme 4.06
8.17
1 year 4.06
Extreme 4.06
8.63
3 years 3.43
Extreme 3.43
8.63
5 years 3.43
Extreme 3.43
12.28
10 years 3.43
Extreme 3.43
23.8
Manager TitleAgeSince
Chief Executive Officer 56 16/03/2020
Director of Finance/CFO 42 28/06/2020
Corporate Officer/Principal 48 16/03/2020
Director TitleAgeSince
Chairman 58 18/05/2014
Chairman 48 31/05/2022
Director/Board Member 56 28/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/11/21 Sell

Executive/Senior Manager

268,300 0.0364%
15/09/21 Sell

Executive/Senior Manager

50,000 0.0068%
26/01/21 Buy

Chairman

29,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%-2.51%-18.07%-22.94% 567M
+0.44%+1.79%+57.72%+128.65% 1,143B
+0.54%+5.30%+45.20%+84.61% 647B
-0.02%+0.37%+25.63%+101.46% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-0.02%-6.16%+61.60%+36.97% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+1.98%+3.07%+54.67%+71.66% 242B
+1.70%+3.71%+35.12%+104.80% 197B
Average +0.25%+0.87%+34.82%+64.81% 402.81B
Weighted average by Cap. +0.23%+0.71%+44.67%+87.18%

Financials

2024 2025
Net sales 852M 128M 115M 106M 95.97M 179M 12.17B 181M 1.27B 505M 6.37B 479M 469M 20.21B 825M 124M 111M 103M 92.91M 174M 11.78B 176M 1.23B 489M 6.16B 464M 454M 19.57B
Net income 9.25M 1.39M 1.24M 1.15M 1.04M 1.95M 132M 1.97M 13.75M 5.48M 69.11M 5.2M 5.09M 219M -91.92M -13.79M -12.37M -11.44M -10.36M -19.35M -1.31B -19.58M -137M -54.46M -687M -51.74M -50.65M -2.18B
Net Debt 974M 146M 131M 121M 110M 205M 13.91B 208M 1.45B 577M 7.28B 548M 537M 23.11B 1B 150M 135M 125M 113M 211M 14.33B 214M 1.49B 595M 7.5B 565M 553M 23.81B
Projected Income Statement - Annual - Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Logo Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Employees
2,170
Date Price Change Volume
27/10/26 CN¥4.670 +0.86% 6,285,700
27/10/26 CN¥4.630 -3.54% 8,692,488
26/10/26 CN¥4.800 +2.56% 7,297,500
23/10/26 CN¥4.680 +1.30% 8,351,133
22/10/26 CN¥4.620 -2.53% 6,090,514
  1. Stock Market
  2. Stocks
  3. 300318 Stock